EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Integrating RNA technologies with CAR-T cell therapy: strategies to overcome current limitations and expand clinical applications

Alexey Yumashev, Matlyuba Sanoyeva, Emma Muradova, Nasiba Khalmatova, Marif Karimov, Akhror Ibragimov, Mukhayya Djumaniyazova, Islombek Umirov, Zhanna R Gardanova

Cancer Chemotherapy and Pharmacology · 05.11.2026 · 96 (1)

DOI: 10.1007/s00280-026-04961-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 05.11.2026. Verfasst von Alexey Yumashev und 8 weiteren Autor:innen. Beteiligte Einrichtung: First Moscow State Medical University, Moscow, Russian Federation. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neoplasms, Receptors, Chimeric Antigen, RNA. Die Arbeit nennt 195 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a prominent cancer treatment modality, demonstrating significant clinical success. To date, several CAR-T products have been approved by the U.S. Food and Drug Administration (FDA) for the management of hematological malignancies. Despite these advances, several challenges continue to limit the broader application of CAR-T therapy. These challenges include complex and costly manufacturing processes, safety concerns associated with integrating viral vectors, individualized production requirements, therapy-related adverse effects, and limited efficacy against solid tumors. Recent progress in ribonucleic acid (RNA)-based technologies has introduced promising strategies to improve the safety, adaptability, and therapeutic performance of CAR-T cells. This review provides a comprehensive translational perspective on the integration of RNA technologies with CAR-T therapy. Specifically, it categorizes current approaches into four key areas: RNA-driven non-viral CAR-T cell manufacturing, RNA vaccine-mediated enhancement of CAR-T activity, RNA interference (RNAi)-based modulation, and in vivo CAR-T cell generation. Among the reviewed approaches, ex vivo messenger RNA (mRNA)-based CAR-T engineering currently has the greatest clinical maturity, whereas RNA vaccine-mediated boosting shows particular promise for enhancing CAR-T expansion and persistence, especially in solid tumors. In vivo RNA-mediated CAR-T generation remains at an early stage of development, with evidence still predominantly derived from preclinical studies, but may ultimately represent the most transformative approach by simplifying manufacturing and improving accessibility.Trial registration number: Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveNeoplasmsReceptors, Chimeric AntigenRNAHumansAnimalsRNA InterferenceT-Lymphocytes

Stichwörter der Autor:innen

CAR-TNon-viral gene deliveryRNA interferenceRNA-based technologiesmRNA engineering

Substanzen

Receptors, Chimeric AntigenRNA

Autor:innen und Institutionen

  • First Moscow State Medical University, Moscow, Russian Federation.
  • Department of Neurology, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan. matlyuba.sanoyeva@bsmi.uz.
  • Department of Microbiology, Virology and Immunology, Samarkand State Medical University, Samarkand, Uzbekistan.
  • University of Economics and Pedagogy, Tashkent, Uzbekistan.
  • Department of Propedeutics of Internal Diseases, Tashkent State Medical University, No. 2, Tashkent, Uzbekistan.
  • Department of Medicine, Termez University of Economics and Service, Termez, Uzbekistan.

Zitieren

APA

Yumashev, A., Sanoyeva, M., Muradova, E., Khalmatova, N., Karimov, M., Ibragimov, A., Djumaniyazova, M., Umirov, I., & Gardanova, Z. R. (2026). Integrating RNA technologies with CAR-T cell therapy: strategies to overcome current limitations and expand clinical applications. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04961-2

Vancouver

Yumashev A, Sanoyeva M, Muradova E, Khalmatova N, Karimov M, Ibragimov A, et al. Integrating RNA technologies with CAR-T cell therapy: strategies to overcome current limitations and expand clinical applications. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04961-2

BibTeX
@article{Yumashev2026,
  author = {Yumashev, Alexey and Sanoyeva, Matlyuba and Muradova, Emma and Khalmatova, Nasiba and Karimov, Marif and Ibragimov, Akhror and Djumaniyazova, Mukhayya and Umirov, Islombek and Gardanova, Zhanna R},
  title = {Integrating RNA technologies with CAR-T cell therapy: strategies to overcome current limitations and expand clinical applications},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04961-2}
}
Kostenlos starten →